Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Associations between concordance with oncology clinical decision support and clinical outcomes in lung cancer patients.
0
Zitationen
20
Autoren
2020
Jahr
Abstract
e14114 Background: Watson for Oncology (WfO) is an artificial intelligence-based clinical decision-support system which provides therapeutic options and associated scientific evidence to cancer-treating physicians. Oncologists at Bumrungrad International Hospital (BIH) have used WfO since 2015. We examined the association between concordance of WfO therapeutic options and BIH treatment decisions with short-term clinical outcomes for lung cancer patients. Methods: This study included lung cancer patients seen at BIH for treatment and follow-up care and for whom WfO was used from 2015 to 2018. Charts were reviewed for concordance with WfO, documentation of disease progression, response to treatment, and survival. We evaluated concordance between oncologists’ treatments and therapeutic options listed as “recommended” by WfO. We evaluated association between WfO concordance and partial or complete response rates over a 24-month period by comparison of proportions with odds ratio. Progression-free survival (PFS, time from diagnosis until progression or death) was evaluated by Kaplan-Meier log-rank test. Results: Seventy-nine lung cancer patients were included. We identified a trend towards higher response rates in concordant cases (59.2%, N = 32), as compared to discordant (48.0%, N = 12), with an odds ratio of 1.56 (see table). There was not a significant difference in PFS between concordant and discordant cohorts. Conclusions: In this small-cohort, retrospective study, lung cancer patients receiving treatments that are concordant with WfO recommended therapeutic options trended towards higher response rates than patients with discordant treatments. Use of a clinical decision-support system may help support cancer-treating physicians in delivering best practice and evidence-based care that may improve short-term outcomes. Prospective studies with larger samples and other cancer types are underway. [Table: see text]
Ähnliche Arbeiten
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2018 · 87.231 Zit.
Cancer statistics, 2020
2020 · 21.262 Zit.
Cancer statistics, 2019
2019 · 20.856 Zit.
Cancer statistics, 2022
2022 · 17.940 Zit.
Cancer statistics, 2018
2018 · 16.922 Zit.
Autoren
- Suthida Suwanvecho
- Harit Suwanrusme
- Tanawat Jirakulaporn
- Palita Lungchukiet
- Nittaya Thanakarn
- Nimit Taechakraichana
- Wimolrat Decha
- Wisanu Boonpakdee
- Pattanawadee Wongrattananon
- Anita M. Preininger
- Metasebya Solomon
- Suwei Wang
- Rezzan Hekmat
- Jaime Esquivel
- Irene Dankwa‐Mullan
- Vimla L. Patel
- Edward H. Shortliffe
- Yull Arriaga
- Gretchen Purcell Jackson
- Narongsak Kiatikajornthada